Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests.

Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G, Berretta M.

Anticancer Drugs. 2013 Nov;24(10):1069-78. doi: 10.1097/CAD.0000000000000002. Review.

PMID:
24025562
2.

Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.

Di Francia R, Siesto RS, Valente D, Spart D, Berretta M.

Eur Rev Med Pharmacol Sci. 2012 Sep;16(9):1211-7. Review.

3.

Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.

Garg MB, Ackland SP.

Cancer Chemother Pharmacol. 2011 Apr;67(4):963-6. doi: 10.1007/s00280-010-1476-9.

PMID:
20976600
4.

Clinical management of oxaliplatin-associated neurotoxicity.

Grothey A.

Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46. Review.

PMID:
15871765
5.

Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.

Di Francia R, De Lucia L, Di Paolo M, Di Martino S, Del Pup L, De Monaco A, Lleshi A, Berretta M.

Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4443-54. Review.

6.

Impact of oxaliplatin-induced neuropathy: a patient perspective.

Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D.

Support Care Cancer. 2012 Nov;20(11):2959-67. doi: 10.1007/s00520-012-1428-5.

PMID:
22426503
7.

Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11199-204. doi: 10.1073/pnas.1305321110.

8.

Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.

Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ.

Clin Colorectal Cancer. 2014 Jun;13(2):73-80. doi: 10.1016/j.clcc.2013.11.004. Review.

PMID:
24365057
9.

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.

Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP.

Cancer. 2013 Oct 1;119(19):3570-7. doi: 10.1002/cncr.28234.

10.

Platinum neurotoxicity pharmacogenetics.

McWhinney SR, Goldberg RM, McLeod HL.

Mol Cancer Ther. 2009 Jan;8(1):10-6. doi: 10.1158/1535-7163.MCT-08-0840. Review.

11.
12.

Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.

Inoue N, Ishida H, Sano M, Kishino T, Okada N, Kumamoto K, Ishibashi K.

Int J Clin Oncol. 2012 Aug;17(4):341-7. doi: 10.1007/s10147-011-0298-z.

PMID:
21833683
13.

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.

Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2009 Mar;45(4):572-8. doi: 10.1016/j.ejca.2008.10.015.

PMID:
19084393
14.

Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy?

Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C.

Free Radic Biol Med. 2013 Aug;61:143-50. doi: 10.1016/j.freeradbiomed.2013.03.019.

PMID:
23548635
15.
16.

Literature review and practical aspects on the management of oxaliplatin-associated toxicity.

Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC.

Clin Colorectal Cancer. 2012 Jun;11(2):93-100. doi: 10.1016/j.clcc.2011.10.004. Review.

PMID:
22154408
17.

[Oxaliplatin neurotoxicity].

Gamelin L, Boisdron-Celle M, Morel A, Gamelin E.

Bull Cancer. 2006 Feb 1;93 Suppl 1:S17-22. Review. French.

PMID:
16491518
18.

Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R.

Support Care Cancer. 2010 Oct;18(10):1263-70. doi: 10.1007/s00520-009-0740-1.

PMID:
19756772
19.

Nerve excitability assessment in chemotherapy-induced neurotoxicity.

Park SB, Lin CS, Kiernan MC.

J Vis Exp. 2012 Apr 26;(62). pii: 3439. doi: 10.3791/3439.

20.

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.

Kobrinsky B, Joseph SO, Muggia F, Liebes L, Beric A, Malankar A, Ivy P, Hochster H.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1073-8. doi: 10.1007/s00280-013-2295-6.

PMID:
24048674
Items per page

Supplemental Content

Support Center